Background and objectives There are few reports on temporary dialysis-requiring AKI as a risk factor for future upper gastrointestinal bleeding (UGIB). This study sought to explore the long-term association between dialysisrequiring AKI and UGIB.
Introduction
The risk of upper gastrointestinal bleeding (UGIB) in patients with CKD (1) or ESRD is reportedly greater than that observed in the general population (1, 2) . Additionally, patients with ESRD who developed UGIB have higher mortality than those without ESRD who developed UGIB (3) (4) (5) (6) . While several uremia-specific factors, including platelet dysfunction and impaired platelet-vessel wall interaction (7, 8) , have been postulated to increase the risk of UGIB and mucosal abnormalities of the gastrointestinal tract, some studies suggest that repeated anticoagulant exposure (8) and the frequent use of ulcerogenic agents, such as nonsteroidal anti-inflammatory drugs (NSAIDs) (1, 9) and antiplatelets (10) , also have important roles.
Because of the advances in critical care medicine and dialysis technologies, an increasing number of hospitalized patients could be discharged alive after AKI (11) (12) (13) (14) (15) (16) (17) . Acute gastrointestinal hemorrhage, especially in the upper gastrointestinal tract, is the most frequent cause of bleeding after AKI (18) . The incidence of shortterm acute gastrointestinal bleeding in hospital stay varies widely in patients with AKI, ranging from 13.4% to 26% (18, 19) . However, few reports have addressed the effect of AKI, especially temporary dialysisrequiring AKI, on the long-term risk of gastrointestinal hemorrhage. We hypothesized that dialysis-requiring AKI is an independent risk factor for UGIB. Specifically, we sought to determine the incidence and risk factors of UGIB after AKI using a nationwide inpatient cohort.
Materials and Methods

Data Source
This population-based cohort study was based on medical information from Taiwan's National Health Insurance (NHI), a nationwide compulsory healthcare program that covers outpatient visits, hospital admissions, prescriptions, interventional procedures, disease profiles, and vital status. The study cohort consisted of 2.6 million patients hospitalized between 1998 and 2006, representing nearly 10% of all NHI enrollees.
Because all personal information was de-identified in the database to protect privacy, no informed consent was required and the study was exempt from a full ethical review by the institutional review board of the National Taiwan University Hospital (201212021RINC).
Study Population
This study included patients age $18 years who developed de novo dialysis-requiring AKI during their index admissions (identified by the procedure codes for acute dialysis) and subsequently recovered from dialysis for 30 days after discharge ( Figure 1 ). Comorbidities were identified from at least three outpatient visits or one inpatient claim within 1 year preceding the index admission. All diagnoses were obtained from International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM), codes. We excluded patients who had AKI or ESRD within 1 year before admission and patients with UGIB or peptic ulcers before or during admission. Also excluded were patients who underwent renal transplantation, vascular access creation for long-term dialysis, or peritoneal-dialysis catheter implantation; those who were hospitalized for .180 days; and those who did not survive for .30 days after discharge ( Figure 2 ). UGIB and peptic ulcers were excluded by ICD-9 codes (Supplemental Table 1 ). AKI was defined by ICD-9 codes for AKI (584. 3, 634.3, 635.3, 636.3, 637.3, 638.3, 639.3, 669.3, 958.5) , as well as by procedure codes for acute dialysis. ESRD was identified under the NHI Scheme by "catastrophic illness certificates" for ESRD on which the commencement dates of long-term dialysis for at least 3 months were recorded.
For comparison, we constructed a control group (non-AKI group), which was selected from the remaining hospitalized patients who did not have a history of AKI, dialysis, and UGIB before and during the index admission and were matched with the study group (AKI-recovery group) on a 1:1 ratio basis according to age, sex, calendar year of index admission, and propensity scores before and during the index hospitalization.
Outcome Measures
Our primary outcome was postdischarge nonvariceal UGIB, which was identified using two modified criteria: a stringent criterion and a lenient criterion as previously reported (Table 1) (20, 21) . By the stringent criterion, UGIB was defined using ICD-9-CM codes that specified the lesions responsible for the hemorrhage (e.g., Mallory-Weiss syndrome, gastric ulcer with hemorrhage). UGIB defined by the lenient criterion encompassed that defined by the stringent criterion and ICD-9-CM codes that did not specify the cause of the bleeding (e.g., hematemesis plus chronic gastric ulcer without mention of hemorrhage, gastrointestinal hemorrhage plus upper gastrointestinal endoscopy performed). Each patient was followed from the date of discharge to the first documented UGIB event and was censored at death or the end of the study (December 31, 2008) , whichever occurred first.
Research Variables
The Charlson comorbidity index (22) was calculated using preadmission comorbidities. The following were recorded during index hospitalization: intensive care unit admission, categories of major surgeries and acute organ dysfunction, and specific acute comorbidities that might be associated with AKI (e.g., severe sepsis, shock, myocardial infarction, hepatorenal syndrome, obstructive uropathy, and exposure to contrast material).
After recovery from acute dialysis, the renal function status was evaluated in mutually exclusive subgroups of non-CKD, CKD, advanced CKD, and ESRD. Because GFR could not be obtained from our insurance database, CKD was defined by ICD-9 codes (23) and advanced CKD was defined by codes for CKD plus simultaneous erythropoiesis-stimulating agent (ESA) treatment. On the basis of the regulation of NHI, ESA can be prescribed only in anemic patients with CKD who have a hematocrit level of #28% and a serum creatinine level of .6 mg/dl (i.e., advanced CKD). Renal status was assessed in two overlapping periods: within 0-90 days of discharge and long term after discharge (at some time from the day of discharge to the day of UGIB, death, or the end of the study). Patients were labeled as having advanced CKD or ESRD in certain periods according to the timing of the commencement of ESA or long-term dialysis. Taking into account the potential confounders of UGIB, we also obtained information on pertinent disorders (e.g., myocardial infarction, atrial fibrillation) and medications from the day of discharge to the day of UGIB, death, or the end of the study. The select medications were proton-pump inhibitors, histamine-2 receptor antagonists, systemic corticosteroids, NSAIDs, aspirin, clopidogrel, warfarin, heparin, and low-molecular-weight heparin (LMWH) (Supplemental Table  2 ). The prevalence of Helicobacter pylori infection was assessed according to treatment with triple or quadruple eradication therapy (24) , defined as a proton-pump inhibitor or histamine-2 receptor antagonist, plus clarithromycin or metronidazole, plus amoxicillin or tetracycline, with or without bismuth.
Statistical Analyses
To reduce the bias in assessing the detrimental effects of AKI, we constructed a comparable non-AKI group using the propensity score method in an attempt to make an unbiased estimate of all the confounders predicting dialysis. Continuous variables are described as mean6SD or median (interquartile range) as appropriate; discrete variables are presented as counts and percentages. We used independent t tests or Mann-Whitney U tests to compare continuous variables and chi-squared tests for categorical ones.
For simplicity and specificity, the following analyses were made under the condition of UGIB defined by the stringent criterion; the outcome defined by the lenient criterion was used only in the sensitivity analysis. Taking into consideration the higher risk of developing CKD or ESRD after AKI and the strong correlations of CKD/ESRD with UGIB and mortality, we used a Cox proportional hazards model with CKD/ESRD as time-dependent covariates (15, 25, 26) , denoted by time-varying CKD/ESRD, to account for the effects of CKD/ESRD developing at some time during follow-up on the risks of UGIB and mortality. Comorbidities and postdischarge medications (use versus nonuse) were also incorporated into the analysis. Variable selection was performed by using stepwise multiple regression, with a p-to-enter and p-to-leave both equal to 0.15. Final results of multivariate analyses were summarized by hazard ratios (HRs) and 95% confidence intervals (CIs).
After obtaining the Cox regression equation, we estimated the hazard function along with the time for a reference patient who did not have AKI during the index hospitalization; did not have AKI, CKD, or ESRD for 10 years after discharge; and had the mean values of all the other covariates for our study patients. On the basis of this hazard function, we further simulated and depicted 10-year survival curves of the probability of freedom from UGIB events under different scenarios of kidney conditions in regard to AKI, CKD, advanced CKD, and ESRD. Specifically, we stratified patients by the status of AKI during index admission and by the renal status after discharge.
All analyses were performed using R software, version 2.15.2 (Free Software Foundation, Inc., Boston, MA). A two-sided P value ,0.05 was considered to represent statistically significant difference.
Results
Patient Characteristics
Among the 4898 patients with de novo transient dialysisrequiring AKI, 4565 were matched with the same number of controls without AKI (Figure 2 ). The average age was 63.6616.5 years, 56.9% of participants were male, and the median preadmission Charlson comorbidity index score was 2 (interquartile range, 0-3) ( Table 2 ). The baseline comorbidities and the proportions of patients undergoing operations were similar in both groups. In the AKI-recovery group, more patients had severe sepsis, hepatorenal syndrome, obstructive uropathy, and exposure to contrast material during hospitalization.
Outcomes
As shown in Table 3 , more AKI-recovery patients received corticosteroids, warfarin, heparin, and LMWH and had CKD, advanced CKD, and ESRD within 0-90 days of discharge and during long-term follow-up. After a median follow-up period of 2.33 years (interquartile range, 0.97-4.81 years), the AKI-recovery group had a higher incidence of UGIB and higher mortality. The incidence rates of UGIB were 50 (by stringent criterion) and 69 (by lenient criterion) per 1000 patient-years in the AKI-recovery group and 31 (by stringent criterion) and 48 (by lenient criterion) per 1000 patient-years in the non-AKI group (both P,0.001). The median time from discharge to the first episode of UGIB according to the stringent criterion was 1.37 years in the AKI-recovery group, which was not statistically different from the 1.22 years in the non-AKI group (P=0.41). Peptic ulcer disease with hemorrhage accounted for 66.2% and 51.7% of the UGIB events in the AKI-recovery and non-AKI groups, respectively (P,0.001). Of note, the number of patients receiving triple or quadruple therapy for H. pylori infection was small. Table 4 shows the clinical predictors of UGIB after we applied the time-varying Cox regression hazards model. In contrast to the non-AKI group, the AKI-recovery group had a higher long-term risk for UGIB (HR, 1.30; 95% CI, 1.14 to 1.48), independent of the effects from other covariates of age, hepatic dysfunction, severe sepsis, corticosteroids, NSAIDs, aspirin, time-varying CKD, advanced CKD, and ESRD. The model exhibited modest discrimination with a c statistic of 0.70 and an adjusted R 2 value of 0.08. Furthermore, the strength of the association between AKI recovery and long-term UGIB was stronger when time-varying CKD/ESRD was not incorporated into the analysis (HR, 1.71; 95% CI, 1.52 to 1.93; P,0.001). Warfarin, heparin, and LMWH were not predictive of UGIB.
For sensitivity analysis, we replaced UGIB defined by the stringent criterion with UGIB defined by the lenient criterion and conducted the time-varying Cox regression model again. The analysis showed that AKI recovery was significantly associated with long-term UGIB as well (HR, 1.23; 95% CI, 1.10 to 1.36; P,0.001), with a c statistic of 0.69 and an adjusted R 2 value of 0.09. We also analyzed the risk factors for mortality by applying the Cox regression model with time-varying covariates. AKI recovery (HR, 1.66; 95% CI, 1.54 to 1.78) and UGIB (HR, 1.24; 95% CI, 1.12 to 1.38) were significantly associated with longterm mortality. The model's prediction ability was good (c statistic=0.77; adjusted R 2 =0.35).
Probability of Freedom from UGIB in the Long Term under Different Scenarios of Morbid Conditions in Regard to AKI, CKD, and ESRD
Our simulation results ( Figure 3) showed AKI recovery had an ominous long-term association with the risk of UGIB compared with a reference hospitalized patient without AKI, CKD, and ESRD for the whole period of 10 years after discharge. Overall, the long-term UGIB-free probability of patients recovering from advanced AKI is sandwiched between that of the reference patient and that of patients with CKD after discharge. Patients with ESRD during follow-up had lower long-term UGIB-free probability than did those with advanced CKD and CKD. There was a trend that the risks for UGIB appeared to be higher among patients whose renal status changed to a worse category during follow-up.
Discussion
To our knowledge, our study is the first to identify that hospitalized patients surviving temporary acute dialysis have higher long-term risk for UGIB and mortality than those without a history of dialysis-requiring AKI. After adjustment for age, comorbidities, and postdischarge drugs, hospitalization for dialysis-requiring AKI remains a significant risk factor for future UGIB, even though the AKI event is momentary. In our statistical models, both CKD and ESRD were handled as time-dependent covariates so that the association between AKI and subsequent UGIB was independent of the development or progression of CKD/ESRD. Moreover, the strength of the association between AKI and UGIB was stronger when CKD/ESRD was not considered, and there was a trend that the risks for UGIB were higher among patients with worse renal status during follow-up. These findings are consistent with the hypothesis that part of the connection between AKI and subsequent UGIB is mediated through the development of CKD/ESRD after AKI. The crude incidence rates of UGIB in our patients with dialysis-requiring AKI were 50 and 69 per 1000 patient-years according to the stringent and lenient criteria, respectively. To our knowledge, this is the only study estimating the longterm incidence of UGIB in patients with AKI based on both inpatient and outpatient claims. In comparison, the incidence of UGIB requiring hospitalization in patients with ESRD was reported to be 23-42 per 1000 patient-years (2, 9) . However, these reports retrieved data only from more severe UGIB that required hospitalization. It is important to stress that approximately 40% of UGIB events reported in the United States Medicare records were managed in an outpatient setting (27) . By also incorporating outpatient claims, a recent population-based study of nearly 1 million patients with ESRD reported an incidence rate of 57 and 328 UGIB episodes per 1000 patient-years, according to the stringent and lenient definitions, respectively (21) . Despite the lack of a head-to-head comparison, the incidence of UGIB in patients recovering from advanced AKI is seemingly lower than that observed in patients with ESRD, but it is still much greater than the occurrence in the general population, for which an overall incidence of 89-112 UGIB events per 100,000 patientyears was reported (28) . Patients with ESRD receiving hemodialysis are frequently exposed to anticoagulants, which undoubtedly augment the bleeding risk. In our study, heparin and LMWH were not predictive of UGIB. Because the number of patients receiving heparin and LMWH was similar to that of ESRD patients, the presence of ESRD might mask the salient effects of heparin and LMWH.
Consistent with the results from our cohorts suggesting that peptic ulcer disease with hemorrhage was the most prominent cause of UGIB in AKI-recovery patients (66.2%), one other study reported that gastroduodenal ulcers accounted for around 60% of UGIB cases viewed with endoscopy in patients with CKD (29) . In another recent population-based study, peptic ulcer disease (35.2%) and gastroduodenitis with hemorrhage (29.1%) were the leading causes of UGIB in patients with ESRD (21, 30) . In brief, the role of peptic ulcer disease with hemorrhage might be more prominent in patients recovering from advanced AKI. Although AKI involves some degree of inflammation (31) (32) (33) , an "immunoparalysis" state, similar to that ensuing from sepsis and critical illness (34, 35) , may coexist and make the effects of H. pylori more pernicious. Our study showed, however, that a small portion of patients received H. pylori eradication therapy. According to a population-based study in Taiwan, H. pylori eradication therapy was given in 24.5%, 31.1%, and 17.1% of patients with uncomplicated, bleeding, and perforated peptic ulcer disease, respectively, and the numbers of prescriptions did not change significantly between 1997 and 2006 (36). Our results suggested that the prevalence of H. pylori infection might be low in this patient population or that our patients were undertreated. The role and prevalence of H. pylori infection in UGIB after advanced AKI require further evaluation.
This study provides evidence that patients recovering from dialysis-requiring AKI have a higher risk of UGIB, although a compelling mechanism linking the two is lacking. Despite all the statistical efforts, our study might overfit this finding or UGIB might be an underappreciated late hazard of advanced AKI through an as-yet-unknown mechanism. Our study has other limitations. The most important stems from the retrospective analysis of administrative billing claims. Previous studies have shown the NHI Research Database is of acceptable quality in providing epidemiologic data, including studies of CKD (37) . Although GFR was unobtainable from the ICD codes, which added difficulty in identifying the CKD stage, a meta-analysis suggested that CKD codes are insensitive but reasonably specific (38) . Since 2004, the rate of misdiagnosing CKD may have been modest in Taiwan because a CKD prevention program has made nearly all patients with CKD diagnosis undergo a nephrology consultation (39, 40) . The second limitation is that we did not analyze the dose and frequency of ulcerogenic drugs in predicting UGIB after AKI. In one study, although the use of ulcerogenic agents was a significant risk factor for peptic ulcer rebleeding in patients with ESRD, a dose-dependent response pattern was not found (6) . The effect of the dose and frequency of ulcerogenic agents on UGIB after advanced AKI remains unsolved.
Another limitation is that our database does not contain data regarding smoking, which is a risk factor for UGIB in patients with ESRD (9) . In light of the idea from the joint modeling of multiple diseases (41), we captured the effect of smoking through investigating its proxies, namely chronic obstructive pulmonary disease, lung cancer, myocardial infarction, and diabetes mellitus, which are highly related to smoking (42, 43) . We found that AKI was associated with UGIB independent of the effects of these proxies, suggesting smoking might not have a significant role in UGIB after AKI.
In conclusion, the current study found that dialysis-requiring AKI was associated with a higher risk of long-term UGIB, and that UGIB was a significant predictor of long-term mortality after AKI. The high accumulation rates of NSAIDs and antiplatelets use after AKI augmented the possibility of UGIB. These findings are of clinical importance for physicians who care for patients surviving advanced AKI.
